Siddharthan, TrishulPollard, Suzanne L.Sekitoleko, IsaacNamazzi, EstherAlupo, PatriciaKalyesubula, RobertKirenga, Bruce2022-05-192022-05-192021Siddharthan, T., Pollard, S. L., Jackson, P., Robertson, N. M., Wosu, A. C., Rahman, N., ... & Kirenga, B. (2021). Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials, 22(1), 1-9.https://doi.org/10.1186/s13063-021-05163-2https://nru.uncst.go.ug/handle/123456789/3260COPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in low- and middle-income country (LMIC) settings. While tobacco-smoke exposure is the most important risk factor for COPD in high-income settings, household air pollution from biomass smoke combustion is a leading risk factor for COPD in LMICs. Despite the high burden of biomass smoke-related COPD, few studies have evaluated the efficacy of pharmacotherapy in this context. Currently recommended inhaler-based therapy for COPD is neither available nor affordable in most resource-limited settings. Low-dose theophylline is an oral, once-a-day therapy, long used in high-income countries (HICs), which has been proposed for the management of COPD in LMICs in the absence of inhaled steroids and/or bronchodilators. The Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD) trial investigates the clinical efficacy and cost-effectiveness of low-dose theophylline for the management of biomass-related COPD in a low-income setting.enBiomass, COPD, TheophyllineArticle